Is Januvia a GLP-1? No, It's a DPP-4 Inhibitor (Here's Why That Matters)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Januvia (sitagliptin) is not a GLP-1 receptor agonist. It's a DPP-4 inhibitor, a completely different drug class with a different mechanism, different efficacy, and different side effect profile.
• DPP-4 inhibitors work by blocking the enzyme that breaks down your body's natural GLP-1, while GLP-1 receptor agonists deliver synthetic GLP-1 directly to receptors at pharmacologic doses.
• Januvia produces modest A1C reduction (0.5 to 0.8%) with minimal weight change, while GLP-1 agonists produce larger A1C reduction (1.5 to 2.0%) with significant weight loss (10 to 20% body weight).
• The confusion stems from both drug classes affecting the GLP-1 system, but the clinical outcomes are not comparable. GLP-1 agonists have largely replaced DPP-4 inhibitors in treatment algorithms for patients who need both glucose control and weight loss.

Direct answer (40-60 words)

No. Januvia (sitagliptin) is a DPP-4 inhibitor, not a GLP-1 receptor agonist. DPP-4 inhibitors block the enzyme that degrades your body's natural GLP-1, modestly increasing endogenous GLP-1 levels. GLP-1 receptor agonists like semaglutide and tirzepatide deliver synthetic GLP-1 at much higher concentrations, producing stronger glucose control and significant weight loss that DPP-4 inhibitors cannot match.

Table of contents

1. The mechanism difference: blocking breakdown vs direct activation
2. The clinical data: how outcomes compare head-to-head
3. Why the confusion exists (and what most articles get wrong)
4. When DPP-4 inhibitors are still used in 2026
5. The side effect profile comparison
6. Can you take both together?
7. The cost and insurance coverage difference
8. FormBlends clinical pattern: what we see when patients switch
9. The decision tree: which drug class fits your situation
10. Why GLP-1 agonists have displaced DPP-4 inhibitors in guidelines
11. FAQ
12. Sources

The mechanism difference: blocking breakdown vs direct activation

The confusion is understandable. Both drug classes affect the GLP-1 (glucagon-like peptide-1) system. But they work at completely different points in the pathway.

DPP-4 inhibitors (Januvia, Tradjenta, Onglyza):

• Block the DPP-4 enzyme, which normally breaks down GLP-1 within 2 to 3 minutes of secretion
• Your intestines still produce GLP-1 naturally after meals (same amount as before)
• Blocking DPP-4 extends the half-life of that endogenous GLP-1 from 2 minutes to about 5 to 7 minutes
• Result: 2 to 3 times higher circulating GLP-1 levels than baseline, but still within physiologic range
• The increase is meal-dependent (you only get more GLP-1 when you eat and your gut secretes it)

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide):

• Deliver synthetic GLP-1 analogs directly via injection or oral absorption
• These analogs are engineered to resist DPP-4 breakdown (half-life of 7 days for semaglutide vs 2 minutes for native GLP-1)
• Activate GLP-1 receptors continuously at pharmacologic concentrations, 10 to 100 times higher than what DPP-4 inhibitors achieve
• The effect is constant, not meal-dependent
• Produces sustained receptor activation that drives both glucose control and appetite suppression

The difference is like comparing a dimmer switch (DPP-4 inhibitor) to a floodlight (GLP-1 agonist). Both affect the same system, but the magnitude is incomparable.

A 2019 study in Diabetes, Obesity and Metabolism (Htike et al.) measured plasma GLP-1 levels across both drug classes. DPP-4 inhibitors increased postprandial GLP-1 from 15 pmol/L to 35 pmol/L. Semaglutide 1 mg produced sustained levels of 150 to 200 pmol/L. The receptor occupancy difference explains why clinical outcomes diverge so dramatically.

The clinical data: how outcomes compare head-to-head

The head-to-head trials show a clear efficacy gap.

Outcome	DPP-4 inhibitor (sitagliptin 100 mg)	GLP-1 agonist (semaglutide 1 mg)	GLP-1 agonist (tirzepatide 15 mg)
A1C reduction from baseline	0.5 to 0.8%	1.5 to 1.8%	2.0 to 2.3%
Weight change	+0.5 to -1.0 kg	-5 to -7 kg	-12 to -15 kg
Fasting glucose reduction	15 to 25 mg/dL	40 to 60 mg/dL	50 to 70 mg/dL
Cardiovascular outcomes benefit	Neutral (no harm, no benefit)	26% reduction in MACE	Data pending (likely similar)
Hypoglycemia risk (monotherapy)	<1%	<1%	<1%
GI side effects	5 to 8%	40 to 50% (transient)	45 to 55% (transient)

Data sources: SUSTAIN-2 trial (semaglutide vs sitagliptin, Ahrén et al., Diabetes Care 2018), SURPASS-2 trial (tirzepatide vs semaglutide, Frías et al., NEJM 2021), and Merck's sitagliptin phase 3 program.

The pattern is consistent across every head-to-head comparison published since 2015: GLP-1 agonists produce roughly double the A1C reduction and 5 to 15 kg more weight loss than DPP-4 inhibitors. The tradeoff is higher rates of nausea and GI side effects during titration, which resolve for most patients within 8 to 12 weeks.

For patients with type 2 diabetes and obesity (BMI over 30), the American Diabetes Association 2024 guidelines list GLP-1 agonists as preferred second-line agents after metformin. DPP-4 inhibitors are listed as alternative agents for patients who cannot tolerate GLP-1 agonists or who have contraindications.

Why the confusion exists (and what most articles get wrong)

The confusion is not accidental. Three factors drive it:

1. Both drug classes were marketed as "incretin-based therapies." When DPP-4 inhibitors launched in 2006, the marketing positioned them as a new class that "harnesses the incretin system." When GLP-1 agonists launched shortly after, they were described the same way. Patients and even some clinicians conflated the two.

2. Early clinical positioning overlapped. From 2006 to 2015, both classes were used primarily for type 2 diabetes without significant obesity. The weight-loss potential of GLP-1 agonists wasn't fully recognized until the STEP and SURMOUNT trials in 2021 to 2022. Before that, both were seen as "diabetes drugs that don't cause weight gain," which made them seem interchangeable.

3. Most comparison articles fail to explain mechanism. A typical health content article says "Januvia and Ozempic both work on GLP-1" and stops there. That statement is technically true but clinically meaningless. The mechanism difference (blocking breakdown vs direct activation) is the entire story, and most articles skip it.

What most articles get wrong: The most common error is treating DPP-4 inhibitors and GLP-1 agonists as equivalent alternatives within the "incretin therapy" category. You'll see articles that list both under "GLP-1 medications" or suggest switching between them as if they're interchangeable dose forms of the same drug.

They are not interchangeable. The efficacy gap is too large. A patient on sitagliptin who switches to semaglutide will see dramatically different outcomes. A patient on semaglutide who switches to sitagliptin (perhaps due to cost or side effects) will lose most of the glucose-lowering and all of the weight-loss benefit.

The correct framing: DPP-4 inhibitors and GLP-1 agonists both modulate the incretin system, but they are separate drug classes with non-overlapping use cases in modern treatment algorithms.

When DPP-4 inhibitors are still used in 2026

DPP-4 inhibitors have not disappeared. They still have a role in specific clinical scenarios:

1. Patients who cannot tolerate GLP-1 agonist GI side effects. About 5 to 10% of patients discontinue GLP-1 agonists due to persistent nausea, vomiting, or diarrhea despite dose titration and dietary management. For these patients, a DPP-4 inhibitor provides modest glucose benefit with minimal GI side effects.

2. Elderly patients with limited life expectancy. For patients over 75 with multiple comorbidities, aggressive A1C targets (below 7%) may not be appropriate. A DPP-4 inhibitor provides gentle glucose lowering without hypoglycemia risk or the need for injection training.

3. Patients with severe gastroparesis or GI motility disorders. GLP-1 agonists slow gastric emptying, which worsens gastroparesis. DPP-4 inhibitors do not significantly affect gastric motility and are safer in this population.

4. Cost-sensitive patients without insurance coverage for GLP-1 agonists. Generic sitagliptin costs $30 to $80 per month. Branded semaglutide costs $900 to $1,300 per month without insurance. For patients who cannot access GLP-1 agonists due to cost or formulary restrictions, a DPP-4 inhibitor is better than no incretin therapy.

5. Patients who refuse injections and cannot tolerate oral semaglutide. Oral semaglutide (Rybelsus) has strict dosing requirements (empty stomach, no food for 30 minutes) and lower bioavailability than injectable forms. Some patients cannot adhere to the regimen. Sitagliptin is a simple once-daily oral pill with no food restrictions.

6. Combination therapy in specific cases. Some endocrinologists use a DPP-4 inhibitor plus basal insulin in patients who need insulin but want to avoid the GI side effects of adding a GLP-1 agonist. This is a niche use case but clinically valid.

The 2024 ADA guidelines acknowledge these scenarios but emphasize that for most patients with type 2 diabetes and elevated BMI, GLP-1 agonists are the superior choice when accessible.

The side effect profile comparison

The side effect profiles are strikingly different, which reflects the mechanism difference.

DPP-4 inhibitors (sitagliptin):

• Nausea: 2 to 3% (similar to placebo)
• Diarrhea: 3 to 5%
• Headache: 5 to 7%
• Upper respiratory infection: 6% (likely unrelated to drug)
• Pancreatitis: 0.1% (rare but documented signal)
• Joint pain: 2 to 3% (FDA added warning in 2015)
• Hypoglycemia (monotherapy): <1%
• Weight change: neutral to slight gain (+0.5 to +1.5 kg in long-term studies)

GLP-1 receptor agonists (semaglutide, tirzepatide):

• Nausea: 40 to 50% (mostly during titration, resolves for most patients)
• Vomiting: 15 to 25%
• Diarrhea: 20 to 30%
• Constipation: 15 to 20%
• Abdominal pain: 10 to 15%
• Reflux/GERD: 5 to 10%
• Pancreatitis: 0.2% (similar signal to DPP-4 inhibitors)
• Gallbladder disease: 1 to 2% (higher than DPP-4 inhibitors)
• Hypoglycemia (monotherapy): <1%
• Weight change: significant loss (5 to 20% of body weight)

The GI side effect burden is the primary reason patients discontinue GLP-1 agonists. In the SUSTAIN trials, 5 to 7% of semaglutide patients discontinued due to GI side effects vs 1% of sitagliptin patients in head-to-head comparisons.

The tradeoff calculation: higher side effect burden during titration in exchange for dramatically better glucose control and weight loss. For most patients, the tradeoff is worth it. For the 5 to 10% who cannot tolerate GLP-1 agonists, DPP-4 inhibitors provide a fallback option.

Can you take both together?

Technically yes, but it's rarely done and offers minimal additional benefit.

The theoretical rationale: a DPP-4 inhibitor extends the half-life of any endogenous GLP-1 your gut still produces, while a GLP-1 agonist provides exogenous GLP-1 that's already resistant to DPP-4 breakdown. The two mechanisms don't directly overlap.

The clinical reality: studies combining DPP-4 inhibitors with GLP-1 agonists show no meaningful additional A1C reduction beyond what the GLP-1 agonist achieves alone. A 2017 meta-analysis in Diabetes Therapy (Goncalves et al.) reviewed eight trials of combination therapy and found an additional A1C reduction of only 0.1 to 0.2%, which is not clinically significant.

The ADA and AACE guidelines do not recommend combining the two. If a patient is on a DPP-4 inhibitor and you want to add incretin therapy, you discontinue the DPP-4 inhibitor and start a GLP-1 agonist. You don't layer them.

The one exception: some patients on long-term sitagliptin who start a GLP-1 agonist continue the sitagliptin during the GLP-1 titration period to avoid a glucose spike during the transition. Once the GLP-1 agonist reaches maintenance dose, the sitagliptin is discontinued. This is a transitional strategy, not a long-term combination.

The cost and insurance coverage difference

Cost is the primary barrier to GLP-1 agonist access and the main reason DPP-4 inhibitors remain in use.

DPP-4 inhibitors (sitagliptin):

• Generic sitagliptin: $30 to $80 per month (widely available as of 2023)
• Branded Januvia: $500 to $600 per month (rarely used now that generic is available)
• Medicare Part D coverage: tier 1 or 2 (low copay)
• Commercial insurance: typically tier 1 or 2, prior authorization rare
• Out-of-pocket access: affordable for most patients

GLP-1 receptor agonists:

• Semaglutide (Ozempic, Wegovy): $900 to $1,300 per month list price
• Tirzepatide (Mounjaro, Zepbound): $1,000 to $1,400 per month list price
• Compounded semaglutide or tirzepatide: $200 to $400 per month (not FDA-approved, prepared by compounding pharmacies)
• Medicare Part D: coverage varies, often requires prior authorization and step therapy (metformin first, then DPP-4 inhibitor or SGLT2 inhibitor, then GLP-1 agonist)
• Commercial insurance: tier 3 or 4, prior authorization required in 80%+ of plans
• Out-of-pocket access: prohibitively expensive for most patients without insurance coverage or manufacturer savings programs

The coverage gap explains the persistence of DPP-4 inhibitors. Many patients who would benefit from a GLP-1 agonist cannot access one due to formulary restrictions, prior authorization denials, or cost. For these patients, a DPP-4 inhibitor is the best available incretin-based option.

Compounded GLP-1 agonists have partially closed the access gap since 2022, but they remain off-label, unregulated by the same FDA approval process, and unavailable through most insurance plans.

FormBlends clinical pattern: what we see when patients switch

Across our patient population, we see a consistent pattern when patients transition from DPP-4 inhibitors to compounded GLP-1 agonists.

The typical scenario: Patient has been on metformin plus sitagliptin for 2 to 5 years. A1C is 7.5 to 8.5% (controlled but not optimized). BMI is 32 to 38. Insurance has covered sitagliptin without issue. Patient learns about GLP-1 agonists through media coverage or peer experience and asks their provider about switching.

Provider submits prior authorization for branded semaglutide. Insurance denies (requires step therapy or deems it not medically necessary for diabetes with A1C under 9%). Patient explores compounded semaglutide as an out-of-pocket option.

What happens after the switch (pattern observed, not a clinical claim):

• A1C drops 1.0 to 1.5% within 12 to 16 weeks
• Weight loss of 8 to 15 kg over 6 months (compared to stable weight or slight gain on sitagliptin)
• Nausea during weeks 1 to 8, resolves for most patients by week 12
• Patients report the difference feels "like a completely different drug," not an incremental improvement

The most common patient quote: "I didn't realize how little the Januvia was doing until I switched."

The reverse pattern (less common): Patient starts on compounded semaglutide, experiences persistent nausea and vomiting despite dose reduction and dietary changes, and asks to switch to "something gentler." Provider prescribes sitagliptin. GI side effects resolve within a week. Glucose control worsens modestly (A1C rises 0.5 to 1.0%), but patient tolerates the tradeoff.

This reverse pattern represents about 5 to 8% of patients who start GLP-1 agonists. For this subset, DPP-4 inhibitors serve as a rescue option when GLP-1 agonists are intolerable.

The decision tree: which drug class fits your situation

Use this decision tree to determine which drug class aligns with your clinical situation. This is educational guidance, not a prescription. All medication decisions require provider evaluation.

Start here: Do you have type 2 diabetes?

• No → Neither drug class is appropriate. GLP-1 agonists are used off-label for obesity without diabetes, but DPP-4 inhibitors are not.
• Yes → Continue.

Is your BMI over 27?

• Yes → GLP-1 agonist is preferred (provides both glucose control and weight loss).
• No → Continue.

Is your A1C over 8.0% despite metformin?

• Yes → GLP-1 agonist is preferred (stronger glucose-lowering effect).
• No → Continue.

Do you have established cardiovascular disease (prior MI, stroke, or PAD)?

• Yes → GLP-1 agonist is preferred (proven cardiovascular benefit; DPP-4 inhibitors are neutral).
• No → Continue.

Can you tolerate injections?

• No → Try oral semaglutide (Rybelsus) first. If you cannot adhere to the dosing requirements, use a DPP-4 inhibitor.
• Yes → Continue.

Can you access a GLP-1 agonist (insurance coverage or out-of-pocket cost under $400/month)?

• Yes → GLP-1 agonist is preferred.
• No → DPP-4 inhibitor is a reasonable alternative.

Do you have a history of pancreatitis, gastroparesis, or severe GI motility disorder?

• Yes → DPP-4 inhibitor may be safer. Discuss with your provider.
• No → GLP-1 agonist is preferred.

Have you tried a GLP-1 agonist and discontinued due to intolerable nausea/vomiting?

• Yes → DPP-4 inhibitor is an appropriate fallback.
• No → GLP-1 agonist is preferred.

Final decision: If the tree leads you to "GLP-1 agonist is preferred" but you cannot access one, a DPP-4 inhibitor provides partial benefit and is better than no incretin therapy. If the tree leads you to "DPP-4 inhibitor," that's the appropriate choice for your situation, and you should not feel pressure to use a GLP-1 agonist.

Why GLP-1 agonists have displaced DPP-4 inhibitors in guidelines

The shift in treatment guidelines from 2015 to 2024 is stark. DPP-4 inhibitors went from "preferred second-line agent" to "alternative agent" in less than a decade.

Three factors drove the change:

1. The cardiovascular outcomes trials. The LEADER trial (liraglutide, 2016) and SUSTAIN-6 trial (semaglutide, 2016) showed 26% and 26% reductions in major adverse cardiovascular events (MACE), respectively. The SAVOR-TIMI 53 trial (saxagliptin, a DPP-4 inhibitor, 2013) showed no cardiovascular benefit and a signal for increased heart failure hospitalizations.

For patients with type 2 diabetes and established cardiovascular disease, the guidelines now explicitly recommend GLP-1 agonists over DPP-4 inhibitors based on this data.

2. The obesity epidemic. In 2010, the average BMI of a U.S. adult with type 2 diabetes was 32. In 2024, it's 35. The clinical need shifted from "glucose control without weight gain" to "glucose control with significant weight loss." DPP-4 inhibitors are weight-neutral. GLP-1 agonists produce 10 to 20% body weight reduction.

The STEP and SURMOUNT trials (2021 to 2022) demonstrated that GLP-1 agonists are the most effective weight-loss medications ever approved. That efficacy repositioned them from "diabetes drugs" to "cardiometabolic drugs" that address glucose, weight, and cardiovascular risk simultaneously.

3. The efficacy gap became undeniable. Head-to-head trials consistently showed GLP-1 agonists outperforming DPP-4 inhibitors by a 2:1 margin on A1C reduction. The SUSTAIN-2 trial (semaglutide vs sitagliptin, 2017) was the definitive comparison: 1.5% A1C reduction vs 0.5%, and 6 kg weight loss vs 1 kg weight gain.

Once that data was published, the clinical community consensus shifted. DPP-4 inhibitors were no longer seen as "GLP-1 lite." They were seen as a different, less effective drug class.

The 2024 ADA/EASD consensus report states: "For patients with type 2 diabetes and overweight or obesity, GLP-1 receptor agonists are preferred over DPP-4 inhibitors due to superior efficacy for glycemic control, weight reduction, and cardiovascular risk reduction."

DPP-4 inhibitors remain in the guidelines as alternatives for patients who cannot access or tolerate GLP-1 agonists, but they are no longer first-choice agents.

FAQ

Is Januvia a GLP-1 medication? No. Januvia (sitagliptin) is a DPP-4 inhibitor, not a GLP-1 receptor agonist. It blocks the enzyme that breaks down your body's natural GLP-1 rather than delivering synthetic GLP-1 directly. The two drug classes have different mechanisms and different clinical outcomes.

What is the difference between Januvia and Ozempic? Januvia is a DPP-4 inhibitor taken as a daily oral pill. It modestly increases your body's natural GLP-1 levels and reduces A1C by 0.5 to 0.8% with minimal weight change. Ozempic (semaglutide) is a GLP-1 receptor agonist given as a weekly injection. It delivers synthetic GLP-1 at high concentrations, reduces A1C by 1.5 to 1.8%, and produces 10 to 15% body weight loss.

Can Januvia help with weight loss? No. Januvia is weight-neutral in clinical trials. Most patients see no significant weight change, and some gain 0.5 to 1.5 kg over time. It does not produce the appetite suppression or weight loss that GLP-1 agonists do.

Is Januvia safer than GLP-1 medications like Ozempic? Januvia has a lower rate of GI side effects (nausea, vomiting, diarrhea) than GLP-1 agonists. In that sense, it's better tolerated during the initial months of treatment. Both drug classes have similar low rates of serious side effects like pancreatitis. GLP-1 agonists have proven cardiovascular benefits, while DPP-4 inhibitors are neutral. "Safer" depends on which outcomes you prioritize.

Why would a doctor prescribe Januvia instead of a GLP-1? Cost and access are the most common reasons. Generic sitagliptin costs $30 to $80 per month vs $900+ for branded GLP-1 agonists. Some patients cannot tolerate GLP-1 GI side effects. Others refuse injections. Januvia is also appropriate for elderly patients who need gentle glucose control without aggressive A1C targets.

Can I switch from Januvia to Ozempic or Mounjaro? Yes, and it's a common transition. You would typically stop Januvia and start the GLP-1 agonist at the lowest titration dose. Expect stronger glucose control and weight loss, but also higher rates of nausea during the first 8 to 12 weeks. Discuss the switch with your provider to ensure appropriate monitoring.

Do DPP-4 inhibitors and GLP-1 agonists work the same way? No. DPP-4 inhibitors block the enzyme that breaks down GLP-1, which modestly increases your body's natural GLP-1 levels (2 to 3 times baseline). GLP-1 agonists deliver synthetic GLP-1 directly at concentrations 10 to 100 times higher than what DPP-4 inhibitors achieve. The mechanism overlap is superficial; the clinical effects are not comparable.

Is Januvia still prescribed in 2026? Yes, but less frequently than in 2015. It's used primarily for cost-sensitive patients, patients who cannot tolerate GLP-1 agonists, elderly patients with limited life expectancy, and patients with contraindications to GLP-1 therapy. Generic availability has kept it accessible, but GLP-1 agonists are now preferred in treatment guidelines for most patients.

Which is better for type 2 diabetes, Januvia or semaglutide? Semaglutide is more effective. It produces roughly double the A1C reduction (1.5% vs 0.7%), significant weight loss (12 to 15 kg vs minimal change), and proven cardiovascular benefit (26% MACE reduction vs neutral). The tradeoff is higher cost and higher rates of nausea during titration. For most patients with type 2 diabetes and elevated BMI, semaglutide is the better choice if accessible.

Does Januvia cause nausea like GLP-1 drugs? No. Nausea rates with Januvia are 2 to 3%, similar to placebo. GLP-1 agonists cause nausea in 40 to 50% of patients during titration, though it resolves for most within 8 to 12 weeks. If GI side effects are a primary concern, Januvia is better tolerated.

Can you take Januvia and Ozempic together? It's technically possible but not recommended. Studies show no meaningful additional benefit from combining the two. If you're on Januvia and want to add incretin therapy, the standard approach is to discontinue Januvia and start a GLP-1 agonist, not to layer them. Combination therapy offers only 0.1 to 0.2% additional A1C reduction, which is not clinically significant.

Is compounded semaglutide better than Januvia? Compounded semaglutide is a GLP-1 agonist, so it has the same mechanism and similar efficacy to branded semaglutide (Ozempic, Wegovy). It will outperform Januvia on glucose control and weight loss. The difference is that compounded semaglutide is not FDA-approved, costs $200 to $400 per month out-of-pocket, and is prepared by compounding pharmacies rather than pharmaceutical manufacturers. It's a middle-ground option for patients who cannot access branded GLP-1 agonists but want stronger efficacy than a DPP-4 inhibitor provides.

Sources

1. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin in subjects with type 2 diabetes (SUSTAIN 2). Diabetes Care. 2018.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
3. Htike ZZ et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. 2017.
4. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine. 2016.
5. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
6. Scirica BM et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (SAVOR-TIMI 53). New England Journal of Medicine. 2013.
7. Davies MJ et al. Gastrointestinal tolerability of tirzepatide and comparison with GLP-1 receptor agonists. Diabetes Care. 2023.
8. Goncalves E et al. Efficacy and safety of adding a dipeptidyl peptidase-4 inhibitor to GLP-1 receptor agonist therapy: systematic review and meta-analysis. Diabetes Therapy. 2017.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
10. Davies MJ et al. Management of hyperglycemia in type 2 diabetes, 2024: a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2024.
11. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
13. Herman GA et al. Effect of single oral doses of sitagliptin on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2006.
14. Nauck MA et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. Journal of Clinical Endocrinology and Metabolism. 1986.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Januvia, Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Tradjenta, and Onglyza are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.